Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006;1(3):229-39.

Pegylated liposomal doxorubicin in ovarian cancer

Andrew E Green  1 , Peter G Rose
Affiliations
Review

Pegylated liposomal doxorubicin in ovarian cancer

Andrew E Green et al. Int J Nanomedicine. 2006.

Abstract

Pegylated liposomal doxorubicin is a formulation of doxorubicin in which the molecule itself is packaged in a liposome made of various lipids with an outer coating of polyethylene glycol. Liposomal technology is being used in increasing amounts in the therapy of a variety of cancers, including ovarian cancers. This article reviews the mechanistic actions of this formulation, the Phase II and Phase III data that helped define the role of pegylated liposomal doxorubicin in recurrent ovarian cancer, as well as a discussion of some of the side-effects and their management.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pegylated liposomal doxorubicin (PLD) molecule. Reprinted with the permission of the Cleveland Clinic Foundation Abbreviations: MPEG-DSPE, N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt.
Figure 2
Figure 2
Scale drawing of the aforementioned (Figure 1) macule in cardiac tissue. Reprinted with the permission of the Cleveland Clinic Foundation.
Figure 3
Figure 3
Pegylated liposomal doxorubicin (PLD) molecule in normal (left) and tumor (right) vessels. Reprinted with the permission of the Cleveland Clinic Foundation.
See this image and copyright information in PMC

References

    1. American Cancer Society. Who gets ovarian cancer? [online] 2006. Accessed 3 March 2006. URL: http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_women_get_...
    1. Androulakis N, Kouroussis C, Mavroudis D, et al. Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours. Eur J Cancer. 2002;38:1992–7. - PubMed
    1. Arcuri C, Sorio R, Tognon G, et al. A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori. 2006;90:556–61. - PubMed
    1. Campos SM, Penson RT, Mays AR, et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001;81:206–12. - PubMed
    1. Campos SM, Matulonis UA, Penson RT, et al. Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mullerian tumors. Gynecol Oncol. 2003;90:610–18. - PubMed

MeSH terms

LinkOut - more resources